fluticasone propionate hydrofluoroalkane (HFA) — Competitive Intelligence Brief

fluticasone propionate hydrofluoroalkane (HFA) (fluticasone propionate hydrofluoroalkane (HFA)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inhaled corticosteroid. Area: Immunology.

marketed Inhaled corticosteroid Glucocorticoid receptors Immunology Small molecule

Target snapshot

fluticasone propionate hydrofluoroalkane (HFA) (fluticasone propionate hydrofluoroalkane (HFA)) — Organon and Co. Fluticasone propionate HFA is a potent inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
fluticasone propionate hydrofluoroalkane (HFA) TARGET	fluticasone propionate hydrofluoroalkane (HFA)	Organon and Co	marketed	Inhaled corticosteroid	Glucocorticoid receptors
Oral Viscous Budesonide (OVB)	Oral Viscous Budesonide (OVB)	Azienda Policlinico Umberto I	marketed	Corticosteroids	Glucocorticoid receptors
Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI	Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI	Orion Corporation, Orion Pharma	marketed	Combination of inhaled corticosteroid (ICS) and long-acting beta2-adrenergic agonist (LABA)	Glucocorticoid receptors and β2-adrenergic receptors
oral mini pulse	oral mini pulse	Cairo University	marketed	Corticosteroids	Glucocorticoid receptors
palonosetron, dexamethasone, and 0.9% NaCl	palonosetron, dexamethasone, and 0.9% NaCl	Sixth Affiliated Hospital, Sun Yat-sen University	phase 3	antiemetic combination	5-HT3 receptors, glucocorticoid receptors
Extra fine Formoterol/Beclomethasone	Extra fine Formoterol/Beclomethasone	National Institute of Respiratory Diseases, Mexico	marketed	Combination inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA)	Beta-2 adrenergic receptor; glucocorticoid receptor
FLOVENT 500mcg	FLOVENT 500mcg	GlaxoSmithKline	marketed	Inhaled corticosteroid (ICS)	Glucocorticoid receptor (GR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inhaled corticosteroid class)

1. AstraZeneca · 10 drugs in this class
2. Teva Branded Pharmaceutical Products R&D, Inc. · 6 drugs in this class
3. GlaxoSmithKline · 5 drugs in this class
4. Chiesi Farmaceutici S.p.A. · 3 drugs in this class
5. West Penn Allegheny Health System · 3 drugs in this class
6. SkyePharma AG · 3 drugs in this class
7. Imperial College London · 2 drugs in this class
8. University Medical Center Groningen · 2 drugs in this class
9. Organon and Co · 2 drugs in this class
10. University of Dundee · 2 drugs in this class